CoChat

Targeting lysosomes in human disease: from basic research to clinical applications

Open access
Cao, Mengdie, Luo, Xiangyuan, Wu, Kongming, He, Xingxing · 2021 · Signal Transduction and Targeted Therapy

The DOI matches its Crossref record; 410 of the 410 references it cites were found in a registry or an index.

Abstract

In recent years, accumulating evidence has elucidated the role of lysosomes in dynamically regulating cellular and organismal homeostasis. Lysosomal changes and dysfunction have been correlated with the development of numerous diseases. In this review, we interpreted the key biological functions of lysosomes in four areas: cellular metabolism, cell proliferation and differentiation, immunity, and cell death. More importantly, we actively sought to determine the characteristic changes and dysfunction of lysosomes in cells affected by these diseases, the causes of these changes and dysfunction, and their significance to the development and treatment of human disease. Furthermore, we outlined currently available targeting strategies: (1) targeting lysosomal acidification; (2) targeting lysosomal cathepsins; (3) targeting lysosomal membrane permeability and integrity; (4) targeting lysosomal calcium signaling; (5) targeting mTOR signaling; and (6) emerging potential targeting strategies. Moreover, we systematically summarized the corresponding drugs and their application in clinical trials. By integrating basic research with clinical findings, we discussed the current opportunities and challenges of targeting lysosomes in human disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-021-00778-y

Cites

410 of 410 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Important events in the development of research into lysosomes as therapeutic targets. Since Christian de Duve discovered and named lysosomes in 1955, scientists have made significant contributions to reveal the structural characteristics and drugs of lysosomes and to connect lysosomes with important pathways such as autophagy, endocytosis, mTOR, and cell death, laying a foundation for the later use of lysosomes as therapeutic targets. Christian de Duve and Yoshinori Ohsumi won the Nobel Prize in 1974 and 2016, respectively, for their contributions to the discovery of lysosomes and the elucidation of autophagy mechanisms. CQ, chloroquine; LSDs, lysosomal storage disorders; CLEAR, coordinated lysosomal expression and regulation; NCCD, Nomenclature Committee on Cell Death
Fig. 1 Important events in the development of research into lysosomes as therapeutic targets. Since Christian de Duve discovered and named lysosomes in 1955, scientists have made significant contributions to reveal the structural characteristics and drugs of lysosomes and to connect lysosomes with important pathways such as autophagy, endocytosis, mTOR, and cell death, laying a foundation for the later use of lysosomes as therapeutic targets. Christian de Duve and Yoshinori Ohsumi won the Nobel Prize in 1974 and 2016, respectively, for their contributions to the discovery of lysosomes and the elucidation of autophagy mechanisms. CQ, chloroquine; LSDs, lysosomal storage disorders; CLEAR, coordinated lysosomal expression and regulation; NCCD, Nomenclature Committee on Cell DeathCC BY · PubMed Central
Fig. 2 Lysosomal structure and function. The lysosome is an acidic membrane-enclosed vesicular organelle containing a variety of hydrolases, and its activity and function are maintained by the channels or pump structures on its surface, such as v-ATPase, iron channels, and nutrient transporters. The lysosome acts not only as the endpoint of multiple trafficking routes, including autophagy, endocytosis, and phagocytosis, but also, as the platform for the recruitment and activation of mTOR, which regulates cell metabolism, growth, and differentiation. Ca2+ released from lysosomal calcium channels such as TRPML also regulates endocytic membrane trafficking, the nuclear transduction of TFEB, and the fusion of lysosomes with other cellular structures, such as autophagosomes and endosomes. However, the leakage of lysosomal contents such as cathepsins, ROS, Fe2+/3+, and Ca2+ contributes to multiple forms of cell death. Exogenous antigens are processed into peptides by lysosomal proteases, and the lysosome also acts as a bilateral switch that mediate both pro-inflammatory and anti-inflammatory processes. The central location of the lysosome in the communication and convergence of multiple pathways determines its pivotal and irreplaceable role in cell metabolism, proliferation, differentiation, immunity, and death. Black arrows indicate positive regulation or metabolite flux, while red arrows indicate negative regulation. mTORC1, mammalian target of rapamycin complex 1; mTORC2, mammalian target of rapamycin complex 2; Arg, arginine; TSC2, tuberous sclerosis complex; AMPK, AMP-activated protein kinase; TFEB, transcription factor EB; RTK, receptor tyrosine kinases; PP2A, protein phosphatase 2 A; TRPML1, transient receptor potential mucolipin 1; v-ATPase, vacuolar H + -adenosine triphosphatase; HSC70, heat shock cognate protein 70; LAMP2A, lysosome-associated membrane protein 2; LMP, lysosomal membrane permeability; MOMP, mitochondrial outer membrane permeabilization; CMA, chaperone-mediated autophagy; TGN, trans-Golgi network; CLEAR, coordinated lysosomal expression and regulation; ROS, reactive oxygen species; RAG, RAS-related GTP-binding protein; Unc-51-like kinase 1 (ULK1); PUMA, p53 upregulated modulator of apoptosis; BID, BH3 interacting domain death agonist; BAX, BCL2-associated X, apoptosis regulator; LDCD, lysosome-dependent cell death
Fig. 2 Lysosomal structure and function. The lysosome is an acidic membrane-enclosed vesicular organelle containing a variety of hydrolases, and its activity and function are maintained by the channels or pump structures on its surface, such as v-ATPase, iron channels, and nutrient transporters. The lysosome acts not only as the endpoint of multiple trafficking routes, including autophagy, endocytosis, and phagocytosis, but also, as the platform for the recruitment and activation of mTOR, which regulates cell metabolism, growth, and differentiation. Ca2+ released from lysosomal calcium channels such as TRPML also regulates endocytic membrane trafficking, the nuclear transduction of TFEB, and the fusion of lysosomes with other cellular structures, such as autophagosomes and endosomes. However, the leakage of lysosomal contents such as cathepsins, ROS, Fe2+/3+, and Ca2+ contributes to multiple forms of cell death. Exogenous antigens are processed into peptides by lysosomal proteases, and the lysosome also acts as a bilateral switch that mediate both pro-inflammatory and anti-inflammatory processes. The central location of the lysosome in the communication and convergence of multiple pathways determines its pivotal and irreplaceable role in cell metabolism, proliferation, differentiation, immunity, and death. Black arrows indicate positive regulation or metabolite flux, while red arrows indicate negative regulation. mTORC1, mammalian target of rapamycin complex 1; mTORC2, mammalian target of rapamycin complex 2; Arg, arginine; TSC2, tuberous sclerosis complex; AMPK, AMP-activated protein kinase; TFEB, transcription factor EB; RTK, receptor tyrosine kinases; PP2A, protein phosphatase 2 A; TRPML1, transient receptor potential mucolipin 1; v-ATPase, vacuolar H + -adenosine triphosphatase; HSC70, heat shock cognate protein 70; LAMP2A, lysosome-associated membrane protein 2; LMP, lysosomal membrane permeability; MOMP, mitochondrial outer membrane permeabilization; CMA, chaperone-mediated autophagy; TGN, trans-Golgi network; CLEAR, coordinated lysosomal expression and regulation; ROS, reactive oxygen species; RAG, RAS-related GTP-binding protein; Unc-51-like kinase 1 (ULK1); PUMA, p53 upregulated modulator of apoptosis; BID, BH3 interacting domain death agonist; BAX, BCL2-associated X, apoptosis regulator; LDCD, lysosome-dependent cell deathCC BY · PubMed Central
Fig. 3 The biogenesis of lysosomes. Lysosomal biogenesis is a combination of cellular biosynthesis and endocytosis pathways. TRPML1 channel, calcineurin, PP2A, and mTORC1 jointly regulate the biosynthesis of lysosomal proteins by modulating the activation and nuclear translocation of TFEB. PP2A, protein phosphatase 2A; mTORC1, mammalian target of rapamycin complex 1; TGN, trans-Golgi network; TFEB, transcription factor EB; CLEAR, coordinated lysosomal expression and regulation
Fig. 3 The biogenesis of lysosomes. Lysosomal biogenesis is a combination of cellular biosynthesis and endocytosis pathways. TRPML1 channel, calcineurin, PP2A, and mTORC1 jointly regulate the biosynthesis of lysosomal proteins by modulating the activation and nuclear translocation of TFEB. PP2A, protein phosphatase 2A; mTORC1, mammalian target of rapamycin complex 1; TGN, trans-Golgi network; TFEB, transcription factor EB; CLEAR, coordinated lysosomal expression and regulationCC BY · PubMed Central
Fig. 4 Available strategies for targeting lysosomes in human disease and their corresponding drugs. Different colors indicate different targeting strategies: red, targeting lysosomal acidification; yellow, targeting lysosomal cathepsins; blue, targeting lysosomal membrane permeability and integrity; green, targeting lysosomal calcium signaling; purple, targeting mTOR signaling; gray, emerging targeting strategies with great potential. The action mechanisms of these drugs are highlighted in bold. mTORC1, mammalian target of rapamycin complex 1; mTORC2, mammalian target of rapamycin complex 2; TRPML1, transient receptor potential mucolipin 1; LMP, lysosomal membrane permeability; ROS, reactive oxygen species; CMA, chaperone-mediated autophagy; CLEAR, coordinated lysosomal expression and regulation; TFEB, transcription factor EB; CQ, chloroquine; HCQ, hydroxychloroquine; QN, quinacrine; PLGA-aNP, poly(DL-lactide-co-glycolide) acidic nanoparticles; AAV, adeno-associated virus; rhCTSD, recombinant human pro-cathepsin D; rhPPCA, recombinant human protective protein/cathepsin A; ASM, acid sphingomyelinase; ZA, zoledronic acid; rhCTSD, recombinant human pro-Cathepsin D; DpdtC, Di-2-pyridylketone dithiocarbamate; Hsp70, heat shock protein 70; HspBP1, Hsp70 binding protein 1; 3,4-DC, 3,4-dimethoxychalcone; PI(3,5)P2, phosphatidyl-(3,5)-bisphosphate; MITF, melanogenesis-associated transcription factor; HPβCD, 2-Hydroxypropyl-β-cyclodextrin; PA, psoromic acid; 3-PEHPC, 3-(3-pyridyl)-2-hydroxy-2-phosphonopropanoic acid; RabGGTase, Rab geranylgeranyl transferase
Fig. 4 Available strategies for targeting lysosomes in human disease and their corresponding drugs. Different colors indicate different targeting strategies: red, targeting lysosomal acidification; yellow, targeting lysosomal cathepsins; blue, targeting lysosomal membrane permeability and integrity; green, targeting lysosomal calcium signaling; purple, targeting mTOR signaling; gray, emerging targeting strategies with great potential. The action mechanisms of these drugs are highlighted in bold. mTORC1, mammalian target of rapamycin complex 1; mTORC2, mammalian target of rapamycin complex 2; TRPML1, transient receptor potential mucolipin 1; LMP, lysosomal membrane permeability; ROS, reactive oxygen species; CMA, chaperone-mediated autophagy; CLEAR, coordinated lysosomal expression and regulation; TFEB, transcription factor EB; CQ, chloroquine; HCQ, hydroxychloroquine; QN, quinacrine; PLGA-aNP, poly(DL-lactide-co-glycolide) acidic nanoparticles; AAV, adeno-associated virus; rhCTSD, recombinant human pro-cathepsin D; rhPPCA, recombinant human protective protein/cathepsin A; ASM, acid sphingomyelinase; ZA, zoledronic acid; rhCTSD, recombinant human pro-Cathepsin D; DpdtC, Di-2-pyridylketone dithiocarbamate; Hsp70, heat shock protein 70; HspBP1, Hsp70 binding protein 1; 3,4-DC, 3,4-dimethoxychalcone; PI(3,5)P2, phosphatidyl-(3,5)-bisphosphate; MITF, melanogenesis-associated transcription factor; HPβCD, 2-Hydroxypropyl-β-cyclodextrin; PA, psoromic acid; 3-PEHPC, 3-(3-pyridyl)-2-hydroxy-2-phosphonopropanoic acid; RabGGTase, Rab geranylgeranyl transferaseCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 410 references

Research works printed but not linked: 6

  1. Patel, S., Homaei, A., El-Seedi, H. R. & Akhtar, N. Cathepsins: Proteases that are vital for survival but can also be fatal. Biomed. Pharmacother.105, 526–532 (2018). · DOI · Paper page
  2. Hockey, L. N. et al. Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition. J. Cell Sci. 128, 232–238 (2015).
  3. Rusmini, P. et al. Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. Autophagy 15, 631–651 (2019). · DOI · Paper page
  4. Marmor, M. F. et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology 123, 1386–1394 (2016). · DOI · Paper page
  5. Peng, W. et al. A distinct inhibitory mechanism of the V-ATPase by Vibrio VopQ revealed by cryo-EM. Nat. Struct. Mol. Biol. 27, 589–597 (2020). · DOI
  6. Mitrofan, L. M., Castells, F. B., Pelkonen, J. & Mönkkönen, J. Lysosomal-mitochondrial axis in zoledronic acid-induced apoptosis in human follicular lymphoma cells. J. Biol. Chem. 285, 1967–1979 (2010). · DOI

Cited by

See all 225

Metadata

Authors
Cao, M., Luo, X., Wu, K., & He, X.
Affiliations
  • Tongji Hospital (CN)
  • Zhengzhou University (CN)
Corresponding author
He, Xingxing
Venue
Signal Transduction and Targeted Therapy
Published
2021-11-08
Volume
6
Issue
1
Pages
379-379
ISSN
2059-3635 (ISSN-L)
OpenAlex
W3214233540
Cited by
225
References
409
Citations by year
2026: 42 · 2025: 78 · 2024: 59 · 2023: 32 · 2022: 14
FWCI
4.02
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (No. 82073095)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Calcium signaling and nucleotide metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
Keywords
lysosomes, lysosomal dysfunction, lysosomal acidification, cathepsins, lysosomal membrane permeability, mTOR signaling, lysosomal storage disease, clinical trials, cellular metabolism, cell death, immunity, cell proliferation and differentiation
MeSH terms
Cathepsins, Cell Differentiation, Cell Membrane Permeability, Humans, Lysosomes, Lysosomal Storage Diseases, Cell Death, Calcium Signaling, Cell Proliferation, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting lysosomes in human disease: from basic research to clinical applications. https://app.cochat.ai/papers/10.1038/s41392-021-00778-y
The paper
Cao, M., Luo, X., Wu, K., & He, X. (2021). Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-021-00778-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.